Regencell Bioscience remains a high-risk, pre-commercial entity characterized by a total absence of consistent revenue and a cumulative retained earnings deficit of $25.2 million. The company's reliance on equity-based funding to support quarterly operating lo...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
The company has failed to generate consistent commercial revenue, with recent quarterly net losses reaching $1.7 million as of 2025Q4.
AI models forecast a 15.0% increase in RGC stock price to $17.16 in 2026, with a 29.32% potential short-term gain based on correlation patterns.
Deep fundamental analysis and smart money sentiment suggest potential investment opportunities in Regencell Bioscience's financial health.
Regencell Bioscience's technology and sector exposure may present growth opportunities, as indicated by expert analysis and market trends.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jun 15, 2026 | -$0.01 vs — | — vs — |
Q3 2026 Jun 11, 2026 | -$0.01 vs — | — vs — |
Q3 2026 Jun 10, 2026 | -$0.01 vs — | — vs — |
Q3 2026 Jun 9, 2026 | -$0.01 vs — | — vs — |
RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth and a PE of 15.7. The company offers a 4.04% forward dividend yield, supported by an 82-year dividend history and consistent annual payout increases.
RGC Resources NASDAQ: RGCO reported fiscal 2026 third-quarter net income of about $550,000, or $0.05 per diluted share, as higher margins supported results despite uneven weather patterns, increased operating expenses and the loss of a large industrial customer.
ROANOKE, Va., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated earnings of $559,000, or $0.05 per diluted share, for the third quarter ended June 30, 2026, compared to $538,000, or $0.05 per diluted share, for the third quarter ended June 30, 2025. Operating margin for the third quarter was $757,000 higher than the equivalent period a year earlier aided by higher non-gas base rates that became effective January 1, 2026. Operating expenses were higher by a similar amount resulting in a nominal decline in operating earnings.
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.
Benchmark RGC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Regencell Bioscience Holdings Limited (RGC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.23 | $3.08B | -865.28 | — | — | -54.81% | — | |
| $6.10 | $2.12B | -10.17 | 698.96% | -88.19% | -49.73% | — | |
| $7.29 | $91.08M | -29.16 | 14.52% | -10.92% | -108.8% | — | |
| $3.26 | $233.82M | 9.88 | -31.8% | -5.14% | -1.53% | — | |
| $4.34 | $17.12M | -0.18 | — | — | -411.58% | — | |
| $300.65 | $8.38B | -22.30 | -100% | — | -34.15% | — |
Regencell Bioscience Holdings Limited (RGC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when RGC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Regencell Bioscience Holdings Limited (RGC) stock FAQ — growth, dividends, profitability & financials explained
Regencell Bioscience Holdings Limited (RGC) reported a net loss of $3.6M for fiscal year 2025.
Regencell Bioscience Holdings Limited (RGC) has a return on equity (ROE) of -54.8%. Negative ROE indicates the company is unprofitable.
Regencell Bioscience Holdings Limited (RGC) had negative free cash flow of $4.0M in fiscal year 2025, likely due to heavy capital investments.
